Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,440 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07299019RecruitingPhase 3
Study of orelabrutinib for secondary progressive MS
This study tests an oral medication called orelabrutinib for people whose multiple sclerosis has changed from relapsing-remitting to secondary progressive. The goal is to see if it can slow down disability worsening that happens even without relapses.
Phoenix, ArizonaAges 18–60 - NCT05671757RecruitingPhase 1/Phase 2
Daratumumab for primary antiphospholipid syndrome
This early-phase study tests daratumumab, an immune-targeting drug, for people with primary antiphospholipid syndrome (APS). It aims to see whether it can reduce APS activity and improve outcomes while you continue your usual blood-thinning treatment.
Baltimore, MarylandAges 18–65 - NCT06507904RecruitingPhase 1
How the body absorbs osivelotor with food or antacid
This study tests how different preparations of the study drug osivelotor are absorbed into the body when taken with food, liquids, or an antacid. Healthy volunteers will receive single doses and have blood samples taken to measure drug levels.
Brussels, Bruxelles-capitale, Région deAges 18–65 - NCT07473778Recruiting
Study of Lenacapavir for HIV Prevention
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
Birmingham, AlabamaAges 18 years+ - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Phoenix, ArizonaAges 18 years+ - NCT07541430RecruitingPhase 2
Testing a New Drug for Desmoid Tumors
This study tests a new medication for adults with desmoid tumors (rare, slow-growing tumors that form in connective tissue). You may qualify if your tumor has grown recently, causes pain, or has come back after previous treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07778498RecruitingPhase 1/Phase 2
Study of a new drug for advanced ovarian cancer and other solid tumors
This study tests an experimental drug called TJ102 for people with advanced ovarian cancer or other solid tumors that have grown despite prior treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06843447RecruitingPhase 1/Phase 2
Study of raludotatug deruxtecan for ovarian cancer
This study tests a new drug called raludotatug deruxtecan for people with certain types of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The drug is designed to target and kill cancer cells while sparing healthy tissue. It may be used alone or with other treatments, depending on the study group.
New Haven, ConnecticutAges 18 years+ - NCT06978725RecruitingPhase 2/Phase 3
Brepocitinib for skin sarcoidosis
This study tests an oral drug called brepocitinib to see if it can help people with skin sarcoidosis and reduce skin symptoms. It aims to find a better treatment option for this condition.
Birmingham, AlabamaAges 18 years+ - NCT07429266RecruitingPhase 3
Study of sapablursen for phlebotomy-dependent polycythemia vera
This trial tests an investigational drug called sapablursen for people with polycythemia vera who still need frequent phlebotomies. The goal is to see if the drug can reduce the need for blood removal and help control the disease safely.
Orange, CaliforniaAges 18 years+ - NCT07776691RecruitingPhase 3
Study of Raludotatug Deruxtecan for Advanced Ovarian Cancer
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07850661Recruiting
Turkish questionnaire on confidence for physical activity
This study involves filling out a Turkish version of a questionnaire called the BARSE, which looks at how confident you feel about doing physical activity. It aims to see if the Turkish version is a reliable and valid tool.
Hatay, AntakyaAges 18–45 - NCT07278479RecruitingPhase 1/Phase 2
Study of a targeted radiation therapy for small cell lung cancer
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
Tampa, FloridaAges 18 years+ - NCT07509034RecruitingPhase 1
Targeted immune cells for recurrent small cell lung cancer
This trial tests a special immune cell therapy (CAR T cells) that targets a protein called B7-H3 on your cancer cells. It is for people with small cell lung cancer or similar neuroendocrine cancers that have returned or not responded to standard treatments.
Bethesda, MarylandAges 18–120 - NCT07774455Recruiting
Pacritinib in real-world settings for myelofibrosis
This study looks at how well pacritinib works in everyday medical practice for people with myelofibrosis, a type of bone marrow disorder. It helps us understand the benefits and risks of this treatment for patients like you.
New Haven, ConnecticutAges 18 years+ - NCT07549321RecruitingPhase 2/Phase 3
Hu14 Immunotherapy for High-Risk Neuroblastoma in Children
This study tests a new antibody-based immunotherapy called hu14 for children and young adults with high-risk neuroblastoma (an aggressive childhood cancer that has spread). The treatment is designed to help the immune system fight cancer cells.
San Francisco, CaliforniaAges 1.5 years–18 years - NCT06889675Recruiting
Yb1-x7 injection for advanced solid tumors
This trial tests an experimental bacteria-based injection into tumors for people with advanced solid tumors. It aims to see if the therapy is safe and possibly effective when standard treatments have failed.
Langfang, HebeiAges 18 years+ - NCT07356154RecruitingPhase 1/Phase 2
Combination treatment for leukemia that has returned or not responded
This study tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has not responded to treatment or has come back. The goal is to see if this combination can help control the disease and improve outcomes.
Duarte, CaliforniaAges 12 years+ - NCT06581432RecruitingPhase 2
Zongertinib for advanced cancers with HER2 changes
This trial tests a new pill called zongertinib for people with advanced cancers that have HER2 changes. It may help when other treatments have stopped working, and it targets the HER2 protein to slow or stop tumor growth.
Anchorage, AlaskaAges 18 years+ - NCT07527858RecruitingPhase 2
Study of denikitug with other treatments for advanced colorectal cancer
This trial tests a new drug called denikitug, alone or combined with other therapies, for people with advanced colorectal cancer that has not responded to earlier treatments. It aims to see if denikitug can help control the cancer.
North Haven, ConnecticutAges 18 years+ - NCT07104032RecruitingPhase 3
Tirabrutinib versus standard chemo for relapsed brain lymphoma
This trial tests a new oral drug called tirabrutinib compared to a standard chemotherapy combination (rituximab and temozolomide) for people whose central nervous system lymphoma has come back or not responded to prior treatment. It aims to see if tirabrutinib can control the lymphoma and improve outcomes.
Phoenix, ArizonaAges 18 years+ - NCT06067451Recruiting
Smart goals for teens with prediabetes
This program helps teens with prediabetes set and reach healthy lifestyle goals. It focuses on weight management and diet changes to help prevent type 2 diabetes.
New York, New YorkAges 10–18 - NCT07884344RecruitingEarly Phase 1
Lixumistat before and after surgery for newly diagnosed glioblastoma
This trial tests a new drug called lixumistat as an early treatment for newly diagnosed glioblastoma, given shortly before and after surgery. The goal is to see if the drug can help fight the tumor and improve outcomes.
Miami, FloridaAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
A study of a new drug for advanced solid tumors
This trial tests a new drug called petosemtamab (MCLA-158) for people with advanced solid tumors that have not responded to other treatments. The drug is designed to target and kill cancer cells. You may be able to participate if you meet the health and cancer history requirements.
La Jolla, CaliforniaAges 18 years+
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,440 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.